Abstract:Macrocyclic compounds, characterized by cyclic structures, often originate from either modified forms of unicyclic canonical molecules or natural products. Within the field of medicinal chemistry, there has been a growing fascination with drug-like macrocycles in recent years, primarily due to compelling evidence indicating that macrocyclization can significantly influence both the biological and physiochemical properties, as well as the selectivity, when compared to their acyclic counterparts. The approval of contemporary pharmaceutical agents like Lorlatinib underscore the notable clinical relevance of drug-like macrocycles. Nonetheless, the synthesis of these drug-like macrocycles poses substantial challenges, primarily stemming from the complexity of ring-closing reactions, which are inherently dependent on the size and geometry of the bridging linker, impacting overall yields. Nevertheless, macrocycles offer a promising avenue for expanding the synthetic toolkit in medicinal chemistry, enabling the creation of bioactive compounds. To shed light on the subject, we delve into the clinical prowess of established macrocyclic drugs, spanning various therapeutic areas, including oncology, and infectious diseases. Case studies of clinically approved macrocyclic agents illustrate their profound impact on patient care and disease management. As we embark on this journey through the world of macrocyclic pharmaceuticals, we aim to provide a comprehensive overview of their synthesis and clinical applications, shedding light on the pivotal role they play in modern medicine.

Unlocking the Drug Potential of the Bryostatin Family: Recent Advances in Product Synthesis and Biomedical Applications

The chemistry and biology of the bryostatins: potential PKC inhibitors in clinical development.

Scalable synthesis of bryostatin 1 and analogs, adjuvant leads against latent HIV

Bryostatin-1: a promising compound for neurological disorders

Bioactive Staurosporine Derivatives from the Streptomyces Sp. NB-A13.

Design, Synthesis and Biological Evaluation of Novel Non-peptide Boronic Acid Derivatives As Proteasome Inhibitors

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Recent developments in the medicinal chemistry of single boron atom-containing compounds

Breaking the Bottleneck in Anticancer Drug Development: Efficient Utilization of Synthetic Biology

Total synthesis of bryostatin 3

Cytotoxic Bryostatin Derivatives from the South China Sea Bryozoan Bugula Neritina

Exploring the synthetic approaches and clinical prowess of established macrocyclic pharmaceuticals

Unlocking the potential of beta-glucans: a comprehensive review from synthesis to drug delivery carrier potency

Design,Synthesis and Biological Activity of Novel Steroidal Bioconjugates

Synthesis of Heterocyclic Ring-Fused Bisnoralcohol Derivatives as Novel Small-Molecule Antiosteoporosis Agents

Boron Chemicals in Drug Discovery and Development: Synthesis and Medicinal Perspective

Andrographolide and its derivatives: Current achievements and future perspectives

Syntheses of Biological Active Natural Products and Natural Product-Like Molecules

Biosynthesis of C-nucleoside antibiotics in actinobacteria: recent advances and future developments

In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication

Recent Advances in the Synthetic Biology of Natural Drugs